Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COX2 Effects on endometrial carcinomas progression.

Pathology, research and practice·2022
Same author

The Road Map for Proton Therapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2018
Same author

Heavy metals effect on breast cancer progression.

Journal of occupational medicine and toxicology (London, England)·2017
Same author

Differentiation between wild-type and vaccines strains of varicella zoster virus (VZV) based on four single nucleotide polymorphisms.

Epidemiology and infection·2017
Same author

The differences in short- and long-term varicella-zoster virus (VZV) immunoglobulin G levels following varicella vaccination of healthcare workers measured by VZV fluorescent-antibody-to-membrane-antigen assay (FAMA), VZV time-resolved fluorescence immunoassay and a VZV purified glycoprotein enzyme immunoassay.

Epidemiology and infection·2016
Same author

Is it appropriate to use fixed assay cut-offs for estimating seroprevalence?

Epidemiology and infection·2015

Related Experiment Video

Updated: Nov 24, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.2K

How Useful is COVID-19 Antibody Testing - A Current Assessment for Oncologists.

P A C Maple1, K Sikora2

  • 1Clinical Neurology Research Group, Division of Clinical Neuroscience, University of Nottingham School of Medicine, Queen's Medical Centre, Nottingham, UK.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|December 22, 2020
PubMed
Summary

COVID-19 antibody tests are crucial for managing cancer patients and infection control, but their reliability is questionable. Many tests lack independent evaluation, leading to confusion about immunity and infection status.

Keywords:
AntibodyCOVID-19SARS-CoV-2lateral flow deviceoncology

More Related Videos

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
05:21

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay

Published on: September 13, 2024

644
Cell-Free Dot Blot as a Practical and Adaptable Immunoassay Platform for the Detection of Antibody Response in Human and Animal Sera
08:21

Cell-Free Dot Blot as a Practical and Adaptable Immunoassay Platform for the Detection of Antibody Response in Human and Animal Sera

Published on: May 23, 2025

677

Related Experiment Videos

Last Updated: Nov 24, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.2K
Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
05:21

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay

Published on: September 13, 2024

644
Cell-Free Dot Blot as a Practical and Adaptable Immunoassay Platform for the Detection of Antibody Response in Human and Animal Sera
08:21

Cell-Free Dot Blot as a Practical and Adaptable Immunoassay Platform for the Detection of Antibody Response in Human and Animal Sera

Published on: May 23, 2025

677

Area of Science:

  • Infectious Diseases
  • Oncology
  • Immunology

Background:

  • The COVID-19 pandemic significantly disrupted cancer care services.
  • Antibody testing for SARS-CoV-2 was proposed for managing high-risk individuals and infection control.
  • Ideally, antibody detection should confirm infection and confer immunity, aiding patient management and healthcare worker return to duty.

Purpose of the Study:

  • To review the benefits and limitations of SARS-CoV-2 antibody testing.
  • To educate healthcare workers, especially in oncology, about antibody test performance.
  • To clarify the complexities of COVID-19 immunity and serological testing.

Main Methods:

  • Literature review of SARS-CoV-2 antibody testing.
  • Analysis of antibody test performance, including sensitivity and specificity.
  • Evaluation of the impact of test variability on clinical decision-making.

Main Results:

  • Immunity after SARS-CoV-2 infection is not always protective, with delayed or absent seroconversion.
  • Variability in antibody test performance, especially lateral flow assays, causes confusion.
  • Many available antibody tests lack independent evaluation and may have inadequate sensitivity and specificity.

Conclusions:

  • SARS-CoV-2 antibody testing has limitations impacting its utility in clinical practice.
  • Healthcare workers need clear guidance on the benefits and drawbacks of available antibody tests.
  • Further research and independent evaluations are necessary to improve the reliability of COVID-19 antibody testing.